Janone (ALTS) Competitors $5.95 -0.01 (-0.17%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ALTS vs. PGEN, TNGX, TRVI, BTMD, SNDL, CMRX, YMAB, VYGR, LFVN, and ITOSShould you be buying Janone stock or one of its competitors? The main competitors of Janone include Precigen (PGEN), Tango Therapeutics (TNGX), Trevi Therapeutics (TRVI), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Janone vs. Precigen Tango Therapeutics Trevi Therapeutics biote SNDL Chimerix Y-mAbs Therapeutics Voyager Therapeutics LifeVantage iTeos Therapeutics Precigen (NASDAQ:PGEN) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Do institutionals & insiders believe in PGEN or ALTS? 33.5% of Precigen shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 44.9% of Precigen shares are owned by company insiders. Comparatively, 4.9% of Janone shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, PGEN or ALTS? Janone has higher revenue and earnings than Precigen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$6.22M52.26-$95.90M-$0.55-2.02Janone$7.11M11.77-$7.81MN/AN/A Does the MarketBeat Community believe in PGEN or ALTS? Precigen received 435 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformPrecigenOutperform Votes43567.34% Underperform Votes21132.66% JanoneN/AN/A Does the media prefer PGEN or ALTS? In the previous week, Precigen had 6 more articles in the media than Janone. MarketBeat recorded 7 mentions for Precigen and 1 mentions for Janone. Janone's average media sentiment score of 0.96 beat Precigen's score of 0.45 indicating that Janone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, PGEN or ALTS? Precigen has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Janone has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Is PGEN or ALTS more profitable? Janone has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Precigen's return on equity of -123.06% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Precigen-3,521.68% -123.06% -87.33% Janone N/A -2,940.01%-39.81% Do analysts rate PGEN or ALTS? Precigen presently has a consensus price target of $6.33, indicating a potential upside of 470.57%. Given Precigen's stronger consensus rating and higher probable upside, research analysts plainly believe Precigen is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPrecigen beats Janone on 9 of the 15 factors compared between the two stocks. Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$83.71M$6.22B$11.78B$9.14BDividend YieldN/A2.94%6.02%4.02%P/E RatioN/A9.8725.2417.36Price / Sales11.77309.2128.3677.11Price / CashN/A61.4417.2635.97Price / Book-8.886.052.654.79Net Income-$7.81M$154.90M$1.04B$225.00M7 Day Performance4.57%-0.32%2.92%2.62%1 Month Performance54.95%0.43%0.91%3.81%1 Year PerformanceN/A3.08%14.70%20.10% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$5.95-0.2%N/AN/A$83.71M$7.11M0.00170Gap UpPGENPrecigen3.9661 of 5 stars$1.07-8.9%$7.00+554.2%-13.3%$313.37M$3.96M-1.95190TNGXTango Therapeutics2.54 of 5 stars$2.86-2.1%$13.14+359.5%-73.9%$307.22M$43.38M-2.4290TRVITrevi Therapeutics3.56 of 5 stars$3.99+4.5%$9.31+133.4%+178.5%$306.70MN/A-9.0720Positive NewsBTMDbiote2.8232 of 5 stars$5.54-1.9%$9.11+64.4%+43.5%$301.03M$193.06M21.31194News CoveragePositive NewsGap DownSNDLSNDL3.5169 of 5 stars$1.80-2.2%$3.25+80.6%+23.6%$298.84M$911.22M-5.812,516Positive NewsCMRXChimerix4.3861 of 5 stars$3.31+1.8%$8.50+156.8%+284.0%$297.69M$159,000.00-3.5290Gap DownYMABY-mAbs Therapeutics2.5421 of 5 stars$6.50-5.7%$20.89+221.4%-34.3%$291.13M$84.55M-12.04150VYGRVoyager Therapeutics4.8895 of 5 stars$5.28-3.1%$15.97+202.4%-32.9%$288.43M$163.78M7.44100LFVNLifeVantage4.3944 of 5 stars$23.00+2.1%$26.00+13.0%+329.0%$288.08M$196.01M71.88260Short Interest ↓ITOSiTeos Therapeutics4.0348 of 5 stars$7.80+0.5%$22.25+185.3%-24.2%$284.97M$35M-2.4890 Related Companies and Tools Related Companies PGEN Alternatives TNGX Alternatives TRVI Alternatives BTMD Alternatives SNDL Alternatives CMRX Alternatives YMAB Alternatives VYGR Alternatives LFVN Alternatives ITOS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALTS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALTS Stock Alerts